"We the public, we the people, developed this drug, we paid for this drug. There's no reason this should be $2,000 a month. People are dying because of it."
By Jake Johnson
May 16, 2019 "Information Clearing House" - During a House hearing on Thursday, Rep. Alexandria Ocasio-Cortez asked the CEO of one of America's largest pharmaceutical companies a simple but crucial question: Why does a life-saving HIV drug that costs $8 a month in Australia have a $2,000 price tag in the U.S.?
Gilead chief executive Daniel O'Day declined to comment on the low price of Truvada for PrEP in Australia, but said the reason the cost is close to $2,000—"the current list price is $1,780," he said—in the United States is because the drug has "patent protection."
As the Washington Post reported in March, the development of Truvada as a treatment for HIV was "almost fully funded by U.S. taxpayers."
The U.S. government patented the treatment in 2015, according to the Post, but has "opted not to file an infringement suit to enforce" the patent even as Gilead—which argues the government patent is invalid—rakes in billions of dollars in profits from Truvada.
Ocasio-Cortez highlighted these facts during the House Oversight and Reform Committee hearing on Thursday.
|
Tired Of The Lies And Non-Stop Propaganda? |
"I think it's important that we notice here that we the public, we the people, developed this drug, we paid for this drug, we led and developed all of the grounding patents to create PrEP, and then that patent has been privatized despite the fact that that patent is owned by the public," said Ocasio-Cortez. "We refuse to enforce it."
"There's no reason this should be $2,000 a month," Ocasio-Cortez added. "People are dying because of it. We own the intellectual property for it. People are dying for no reason. For no reason. We developed this drug."
|
Are You Tired Of The Lies And Non-Stop Propaganda? |
